Enlivex Ltd (ENLV) News & EventsENLVEnlivex Ltd

Enlivex Reports 12-Month Clinical Data for Allocetra

Enlivex announced favorable 12-month topline data from the Phase IIa stage of its Phase I/IIa trial evaluating Allocetra in patients with moderate to severe knee osteoarthritis. In patients aged 64 and older, 79.2% achieved a clinically meaningful response, with reduced pain and improved knee function, in the Allocetra group, compared to 47.6% in the placebo group at 12 months. No treatment-related serious adverse events were observed. The 12-month data will be presented at the American College of Rheumatology Convergence on November 8. "The 12-month results show that a single treatment cycle of Allocetra delivered a clinically meaningful benefit in older patients with knee osteoarthritis that was sustained through one year. In a disease with no approved disease-modifying therapies, where treatment is largely limited to symptom management or surgery, a durable response from a single treatment cycle could offer a differentiated profile for patients, physicians and payers. We are pleased that these data were selected for presentation at ACR Convergence 2026, and we look forward to topline data from our Phase IIb trial, which is enrolling this same population, by the end of the second quarter of 2027," said Oren Hershkovitz, CEO of Enlivex.

Enlivex Completes First Injection for 135 Patients in Allocetra Trial

Enlivex announced that 135 patients, out of a total planned 182, have been randomized and were administered the first injection of Allocetra in the company's Phase 2b clinical trial of Allocetra for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis. The trial is actively recruiting at clinical sites in the United States, Denmark and Poland, and the Company expects to report topline six-month data by mid-2027.

Enlivex Implements Cost Reduction Plan, Cuts Workforce by 60%

Enlivex announced a cost reduction plan, effective immediately, designed to substantially reduce the company's cash burn and focus its resources on the execution of its Phase 2b clinical trial of Allocetra for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, or OA. The company expects to report topline six-month data from the trial by mid-2027. The company is winding down, effective immediately, all research and development activities not related to the Phase 2b clinical trial. The company's resources will be dedicated to the execution of the Phase 2b trial and related activities. The company is reducing its workforce by approximately 60%. Salaries for the company's management team will be reduced by 20%, and the CEO's will be reduced by 40%.